Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11238980 | 0.83 | CA2 (0.59) | CA2TTR | |
| SCHEMBL632874 | 0.83 | — | — | |
| Sulfuric Acid SCHEMBL8008480 | 0.80 | CA2 (0.60) | CA2 | |
| Dioxane SCHEMBL18190958 | 0.75 | TTR (0.38) | CA2TTR | |
| SCHEMBL6533129 | 0.74 | CA2 (0.53) | CA2 | |
| Dioxane SCHEMBL1565192 | 0.73 | CA5A (0.50) | CA2TTR | |
| Dioxane SCHEMBL18190957 | 0.73 | CA5A (0.50) | CA2TTR | |
| Trimethylammonium SCHEMBL3147628 | 0.72 | CA2 (0.50) | CA2 | |
| Morpholine SCHEMBL11598863 | 0.70 | MEN1 (0.50) | CA2 | |
| Dioxane SCHEMBL28184520 | 0.70 | CA5A (0.46) | CA2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044065-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | DOLPHIN DAVID H (CA) | 2004-03-04 | — | — | US | claimed |
| EP-1296721-A2 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING AND THERAPY | The University of British Columbia (CA) | 2003-04-02 | — | — | EP | claimed |
| US-20020102209-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | UNIVERSITE DE SHERBROOKE (CA) | 2002-08-01 | — | — | US | claimed |
| WO-2001080906-A9 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING A THERAPY | UNIV BRITISH COLUMBIA (CA) | 2002-02-21 | — | — | WO | claimed |
| WO-2001080906-A2 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING A THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-01 | — | — | WO | claimed |
| US-20040044065-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | DOLPHIN DAVID H (CA) | 2004-03-04 | — | — | US | disclosed |
| US-6613304-B2 | For imaging renal tissues | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-09-02 | — | — | US | disclosed |
| EP-1296721-A2 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING AND THERAPY | The University of British Columbia (CA) | 2003-04-02 | — | — | EP | disclosed |
| US-20020102209-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | UNIVERSITE DE SHERBROOKE (CA) | 2002-08-01 | — | — | US | disclosed |
| WO-2001080906-A9 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING A THERAPY | UNIV BRITISH COLUMBIA (CA) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001080906-A2 | RADIOMETAL COMPLEXES OF 2-PYRROLYLTHIONES FOR IMAGING A THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102209-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | MPI, PYCR1, PAICS | CA2 3534/4885TTR 608/4885 |
| US-20040044065-A1 | Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy | MPI, PYCR1, PAICS | CA2 3534/4885TTR 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.